Lord, Abbett & Co
NAMS icon

Lord, Abbett & Co’s NewAmsterdam Pharma NAMS Stock Holding History

Lord, Abbett & Co’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.4M Buy
306,560
+111,205
+57% +$3.66M 0.03% 382
2026
Q1 		$6.25M Sell
195,355
-5,283
-3% -$172K 0.02% 426
2025
Q4 		$7.04M Buy
+200,638
New +$7.3M 0.02% 422

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Lord, Abbett & Co's NAMS Position: Q2 2026 in Review

Lord, Abbett & Co increased its NewAmsterdam Pharma (NAMS) stake by 57% in Q2 2026, buying an estimated $3.66M and bringing the position to 306,560 shares worth $10.4M. The position accounts for 0.03% of the portfolio, ranked #382.

Lord, Abbett & Co first reported a position in NAMS in Q4 2025 and has held it in 3 quarters since. 195 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • Lord, Abbett & Co held 306,560 shares of NewAmsterdam Pharma worth $10.4M as of Q2 2026.
  • Lord, Abbett & Co bought 111,205 NewAmsterdam Pharma shares in Q2 2026, an estimated $3.66M.
  • NewAmsterdam Pharma made up 0.03% of Lord, Abbett & Co's portfolio in Q2 2026, its #382 holding.
  • Lord, Abbett & Co first reported a position in NewAmsterdam Pharma in Q4 2025 and has held it in 3 quarters since.
  • 195 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Lord, Abbett & Co's 13F filing for Q2 2026, filed 14 Aug 2026.